Cardiovascular and Soft Tissue Repair Patches Market Analysis By Application [Cardiac Repair (Atrial Septal Defect, Common Atrium, Defects Of The Endocardial Cushion, Tetralogy Of Fallot, Others), Vascular Repair & Reconstruction (Carotid Endarterectomy, Anomalous Connection Of The Pulmonary Veins, Transposition Of The Great Vessels, Others), Pericardial Repair, Dural Repair, Soft Tissue Repair (Defects Of The Abdominal Wall, Defects Of The Thoracic Wall, Gastric Binding, Hernias)], By Raw Material (Eptfe, Biomaterial And Tissue Engineered Material, Others) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Published date: Feb 2024
Report ID: 53529
Number of Pages: 381
Format:

Fact Checked

Cite this Research

- 1. Cardiovascular and Soft Tissue Repair Patches Market Introduction
  - 1.1. Definition
  - 1.2. Taxonomy
  - 1.3. Research Scope
- 2. Executive Summary
  - 2.1. Key Findings by Major Segments
  - 2.2. Top strategies by Major Players
- 3. Global Cardiovascular and Soft Tissue Repair Patches Market Overview
  - 3.1. Cardiovascular and Soft Tissue Repair Patches Market Dynamics
    
    3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
  - 3.2. PESTLE Analysis
  - 3.3. Opportunity Map Analysis
  - 3.4. PORTER'S Five Forces Analysis
  - 3.5. Market Competition Scenario Analysis
  - 3.6. Product Life Cycle Analysis
  - 3.7. Opportunity Orbits
  - 3.8. Production Analysis by Region/Company
  - 3.9. Industry chain Analysis
  - 3.10. Marketing Strategy
- 4. Global Cardiovascular and Soft Tissue Repair Patches Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
  - 4.1. Global Cardiovascular and Soft Tissue Repair Patches Market Analysis by Type: Introduction
  - 4.2. Market Size and Forecast by Region
  - 4.3. ePTFE
  - 4.4. Tissue Engineered Material
  - 4.5. Other
- 5. Global Cardiovascular and Soft Tissue Repair Patches Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
  - 5.1. Global Cardiovascular and Soft Tissue Repair Patches Market Analysis by Application: Introduction
  - 5.2. Market Size and Forecast by Region
  - 5.3. Vascular Repair
  - 5.4. Pericardial Repair
  - 5.5. Dural Repair
  - 5.6. Soft Tissue Repair
- 6. Global Cardiovascular and Soft Tissue Repair Patches Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
  - 6.1. North America
    
    6.1.1. North America Cardiovascular and Soft Tissue Repair Patches Market: Regional Trend Analysis
    
    6.1.1.1. US
    
    6.1.1.2. Canada
    
    6.1.1.3. Mexico
  - 6.2.1. Europe
    
    6.2.1. Europe Cardiovascular and Soft Tissue Repair Patches Market: Regional Trend Analysis
    
    6.2.1.1. Germany
    
    6.2.1.2. France
    
    6.2.1.3. UK
    
    6.2.1.4. Russia
    
    6.2.1.5. Italy
    
    6.2.1.6. Spain
    
    6.2.1.7. Rest of Europe
  - 6.3. Asia-Pacific
    
    6.3.1. Asia-Pacific Cardiovascular and Soft Tissue Repair Patches Market: Regional Trend Analysis
    
    6.3.1.1. China
    
    6.3.1.2. Japan
    
    6.3.1.3. Korea
    
    6.3.1.4. India
    
    6.3.1.5. Rest of Asia-Pacific
  - 6.4. Latin America
    
    6.4.1. Latin America Cardiovascular and Soft Tissue Repair Patches Market: Regional Trend Analysis
    
    6.4.1.1. Brazil
    
    6.4.1.2. Argentina
    
    6.4.1.3. Rest of Latin America
  - 6.5. Middle East and Africa
    
    6.5.1. Middle East and Africa Cardiovascular and Soft Tissue Repair Patches Market: Regional Trend Analysis
    
    6.5.1.1. GCC
    
    6.5.1.2. South Africa
    
    6.5.1.3. Israel
    
    6.5.1.4. Rest of MEA
- 7. Global Cardiovascular and Soft Tissue Repair Patches Market Competitive Landscape, Market Share Analysis, and Company Profiles
  - 7.1. Market Share Analysis
  - 7.2. Company Profiles
  - 7.3. Baxter
    
    7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
  - 7.4. Admedus
    
    7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
  - 7.5. St Jude Medical
    
    7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
  - 7.6. LeMaitre Vascular Inc.
    
    7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
  - 7.7. Biointegral Surgical#Inc.
    
    7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
  - 7.8. Edwards Life Sciences Corporation
    
    7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
  - 7.9. Glycar SA Pty Ltd.
    
    7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
  - 7.10. LabCor
    
    7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
  - 7.11. Cryolife#Inc.
    
    7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
  - 7.12. CorMatrix
    
    7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
  - 7.13. Terumo Medical Corporation
    
    7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
  - 7.14. Bard Peripheral Vascular Inc.
    
    7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments
  - 7.15. Neovasc
    
    7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments
  - 7.16. W.L. Gore & Associates#Inc.
    
    7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments
  - 7.17. B.Braun
    
    7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments
  - 7.18. Novomedics
    
    7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
  - 7.19. TEI Biosciences Inc.
    
    7.19.1. Company Overview
    
    7.19.2. Financial Highlights
    
    7.19.3. Product Portfolio
    
    7.19.4. SWOT Analysis
    
    7.19.5. Key Strategies and Developments
  - 7.20. Perouse Medical
    
    7.20.1. Company Overview
    
    7.20.2. Financial Highlights
    
    7.20.3. Product Portfolio
    
    7.20.4. SWOT Analysis
    
    7.20.5. Key Strategies and Developments
  - 7.21. Gunze Limited
    
    7.21.1. Company Overview
    
    7.21.2. Financial Highlights
    
    7.21.3. Product Portfolio
    
    7.21.4. SWOT Analysis
    
    7.21.5. Key Strategies and Developments
  - 7.22. Atriummed
    
    7.22.1. Company Overview
    
    7.22.2. Financial Highlights
    
    7.22.3. Product Portfolio
    
    7.22.4. SWOT Analysis
    
    7.22.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- Baxter
- Abbott
- Glycar SA Pty Ltd.
- LabCor
- Cryolife Inc.
- Terumo Medical Corporation
- W.L. Gore & Associates Inc.
- TEI Biosciences Inc.
- Neovasc
- Integra LifeSciences Corporation